{Reference Type}: Case Reports
{Title}: Bronchiectasis, lymphadenopathies related to BAFF overexpression and lymphoplasmacytic cystitis as adverse events associated with prolonged use of rituximab in systemic autoimmune rheumatic diseases.
{Author}: Cañas CA;Posso-Osorio I;Pérez-Uribe V;Erazo-Martínez V;
{Journal}: Rev Clin Esp (Barc)
{Volume}: 224
{Issue}: 7
{Year}: 2024 Aug-Sep 5
暂无{DOI}: 10.1016/j.rceng.2024.06.001
{Abstract}: <B>BACKGROUND: </B>The long-term use of rituximab (RTX) has been gaining ground in the treatment of systemic autoimmune diseases. The adverse events (AEs) associated with its use different to infections are being reported.<BR><B>METHODS: </B>A cohort of patients with SAIDs treated at a high-complexity center in Cali (southwestern Colombia) with follow-up from January 2008 to December 2022 were examined to search for potential AEs associated with prolonged use of RTX.<BR><B>RESULTS: </B>From 178 patients with long-term use of RTX 3 (1.68%) had lymphadenopathies with lymphoid follicular hyperplasia related to BAFF overexpression, 4 (2.24%) with bronchiectasis, and 4 (2.24%) with lymphoplasmacytic cystitis.<BR><B>CONCLUSIONS: </B>Bronchiectasis, lymphoid follicular hyperplasia related to BAFF overexpression, and lymphoplasmacytic cystitis may be life-threatening long-term AEs in patients with prolonged use of RTX.